{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:06:15Z","timestamp":1790791575237,"version":"4.1.0"},"reference-count":227,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Nations\u2019 ongoing struggles with a number of novel and reemerging infectious diseases, including the ongoing global health issue, the SARS-Co-V2 (severe acute respiratory syndrome coronavirus 2) outbreak, serve as proof that infectious diseases constitute a serious threat to the global public health. Moreover, the fatality rate in humans is rising as a result of the development of severe infectious diseases brought about by multiple drug-tolerant pathogenic microorganisms. The widespread use of traditional antimicrobial drugs, immunosuppressive medications, and other related factors led to the establishment of such drug resistant pathogenic microbial species. To overcome the difficulties commonly encountered by current infectious disease management and control processes, like inadequate effectiveness, toxicities, and the evolution of drug tolerance, new treatment solutions are required. Fortunately, immunotherapies already hold great potential for reducing these restrictions while simultaneously expanding the boundaries of healthcare and medicine, as shown by the latest discoveries and the success of drugs including monoclonal antibodies (MAbs), vaccinations, etc. Immunotherapies comprise methods for treating diseases that specifically target or affect the body\u2019s immune system and such immunological procedures\/therapies strengthen the host\u2019s defenses to fight those infections. The immunotherapy-based treatments control the host\u2019s innate and adaptive immune responses, which are effective in treating different pathogenic microbial infections. As a result, diverse immunotherapeutic strategies are being researched more and more as alternative treatments for infectious diseases, leading to substantial improvements in our comprehension of the associations between pathogens and host immune system. In this review we will explore different immunotherapies and their usage for the assistance of a broad spectrum of infectious ailments caused by various human bacterial and fungal pathogenic microbes. We will discuss about the recent developments in the therapeutics against the growing human pathogenic microbial diseases and focus on the present and future of using immunotherapies to overcome these diseases.<\/jats:p><jats:p><jats:fig><jats:label>Graphical Abstract<\/jats:label><jats:caption><jats:p>The graphical abstract shows the therapeutic potential of different types of immunotherapies like vaccines, monoclonal antibodies-based therapies, etc., against different kinds of human Bacterial and Fungal microbial infections.<\/jats:p><\/jats:caption><\/jats:fig><\/jats:p>","DOI":"10.3389\/fmed.2023.1135541","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T08:07:03Z","timestamp":1681718823000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Immunotherapies against human bacterial and fungal infectious diseases: A review"],"prefix":"10.3389","volume":"10","author":[{"given":"Hafsa","family":"Qadri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Haseeb","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustfa","family":"Alkhanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Almilaibary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manzoor Ahmad","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"ref1","first-page":"19","article-title":"Emerging and re-emerging infections in India: an overview","volume":"138","author":"Dikid","year":"2013","journal-title":"Indian J Med Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/35021206","article-title":"Changing patterns of infectious disease","volume":"406","author":"Cohen","year":"2000","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4103\/1995-7645.277535","article-title":"Emerging and re-emerging human infectious diseases: a systematic review of the role of wild animals with a focus on public health impact","volume":"13","author":"Cupertino","year":"2020","journal-title":"Asian Pac J Trop Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1016\/S2666-5247(21)00173-7","article-title":"Rising antimicrobial resistance: an evolving epidemic in a pandemic","volume":"2","author":"Manesh","year":"2021","journal-title":"Lancet Microbe"},{"key":"ref5","author":"O\u2019Neill","year":"2016"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1179\/2047773215Y.0000000030","article-title":"Antimicrobial resistance: a global multifaceted phenomenon","volume":"109","author":"Prestinaci","year":"2015","journal-title":"Pathog Glob Health"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13756-017-0208-x","article-title":"The threat of antimicrobial resistance in developing countries: causes and control strategies","volume":"6","author":"Ayukekbong","year":"2017","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.mmcr.2020.06.005","article-title":"Multi-triazole-resistant aspergillus fumigatus and SARS-CoV-2 co-infection: a lethal combination","volume":"31","author":"Mohamed","year":"2021","journal-title":"Med Mycol Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/jof6030163","article-title":"Pan-echinocandin-resistant Candida glabrata bloodstream infection complicating COVID-19: a fatal case report","volume":"6","author":"Posteraro","year":"2020","journal-title":"J Fungi"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13756-020-00819-1","article-title":"Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis","volume":"9","author":"Li","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13613-020-00736-x","article-title":"Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU","volume":"10","author":"Contou","year":"2020","journal-title":"Ann Intensive Care"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.cell.2020.04.042","article-title":"Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection","volume":"181","author":"Netea","year":"2020","journal-title":"Cells"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"106324","DOI":"10.1016\/j.ijantimicag.2021.106324","article-title":"Increased antimicrobial resistance during the COVID-19 pandemic","volume":"57","author":"Lai","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1042\/EBC20160017","article-title":"The immune system","volume":"60","author":"Nicholson","year":"2016","journal-title":"Essays Biochem"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4018\/978-1-7998-5563-7.ch013","article-title":"Nanomedicine in human health therapeutics and drug delivery: nanobiotechnology and nanobiomedicine","author":"Mir","year":"2021","journal-title":"Applications of Nanomaterials in Agriculture, Food Science, and Medicine"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/NIB-140082","article-title":"Inflammatory mechanisms as potential therapeutic targets in stroke","volume":"5","author":"Mir","year":"2014","journal-title":"Adv. Neuroimmune Biol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.12816\/0004774","article-title":"Tuberculosis time bomb-A global emergency: Need for alternative vaccines","volume":"1","author":"Mir","year":"2013","journal-title":"J. Health Sci."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2174\/157339507781483487","article-title":"Influence of CD80 and CD86 co-stimulation in the modulation of the activation of antigen presenting cells","volume":"3","author":"Mir","year":"2007","journal-title":"Curr. Immunol. Rev."},{"key":"ref19","volume-title":"Innate\u2013effector immune response elicitation against tuberculosis through anti-b7-1 (CD80) and anti-b7-2 (CD86) signaling in macrophages","author":"Mir","year":"2013"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/b978-0-12-802585-7.00001-7","article-title":"Introduction to costimulation and costimulatory molecules","author":"Mir","year":"2015","journal-title":"Developing costimulatory molecules for immunotherapy of diseases."},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-96127-1.00001-2","volume-title":"Significance of immunotherapy for human fungal diseases and antifungal drug discovery","author":"Mir","year":"2022"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-96127-1.00004-8","volume-title":"Significance of immunotherapy for human bacterial diseases and antibacterial drug discovery","author":"Mir","year":"2022"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.2174\/1389450121666201228123212","article-title":"Novel strategies to combat the emerging drug resistance in human pathogenic microbes","volume":"22","author":"Qadri","year":"2021","journal-title":"Curr Drug Targets"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"126725","DOI":"10.1016\/j.micres.2021.126725","article-title":"Glucose-The X factor for the survival of human fungal pathogens and disease progression in the host","volume":"247","author":"Qadri","year":"2021","journal-title":"Microbiol. Res."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"103376","DOI":"10.1016\/j.sjbs.2022.103376","article-title":"Natural products and their semi-synthetic derivatives against antimicrobial-resistant human pathogenic bacteria and fungi","volume":"18","author":"Qadri","year":"2022","journal-title":"Saudi J. Biol. Sci."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"s8","DOI":"10.1016\/S0966-842X(02)02429-0","article-title":"Microbial and viral drug resistance mechanisms","volume":"10","author":"McKeegan","year":"2002","journal-title":"Trends Microbiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.20506\/rst.31.1.2111","article-title":"Clinical impact of antimicrobial resistance in humans","volume":"31","author":"Collignon","year":"2012","journal-title":"Rev Sci Tech"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-96127-1.00013-9","volume-title":"Evolution of antimicrobial drug resistance in human pathogenic bacteria","author":"Mir","year":"2022"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-96127-1.00009-7","volume-title":"Evolution of antimicrobial drug resistance in human pathogenic fungi.","author":"Mir","year":"2022"},{"key":"ref30","first-page":"277","article-title":"The antibiotic resistance crisis: part 1: causes and threats","volume":"40","author":"Ventola","year":"2015","journal-title":"Pharm Ther"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1995-7645(11)60149-1","article-title":"Cholera: a great global concern","volume":"4","author":"Mandal","year":"2011","journal-title":"Asian Pac J Trop Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1874279301004010038","article-title":"Update on antibacterial resistance in low-income countries: factors favoring the emergence of resistance","volume":"4","author":"Vila","year":"2010","journal-title":"Open Infect Dis J"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-019-0660-8","article-title":"Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges","volume":"11","author":"Cohen","year":"2019","journal-title":"Genome Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/femsre\/fux011","article-title":"Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives","volume":"41","author":"Gygli","year":"2017","journal-title":"FEMS Microbiol Rev"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.3390\/ijms22063128","article-title":"Pseudomonas aeruginosa: an audacious pathogen with an adaptable arsenal of virulence factors","volume":"22","author":"Jurado-Mart\u00edn","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fcimb.2017.00039","article-title":"Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence","volume":"7","author":"Moradali","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.7754\/Clin.Lab.2020.200930","article-title":"Staphylococcus aureus, ESKAPE bacteria challenging current health care and community settings: a literature review","volume":"67","author":"Tigabu","year":"2021","journal-title":"Clin Lab"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/microorganisms7050138","article-title":"Community-and hospital-acquired Klebsiella pneumoniae urinary tract infections in Portugal: virulence and antibiotic resistance","volume":"7","author":"Caneiras","year":"2019","journal-title":"Microorganisms"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1556\/030.66.2019.006","article-title":"Antibiotic resistance, virulence and genetic diversity of Klebsiella pneumoniae in community-and hospital-acquired urinary tract infections in Iran","volume":"66","author":"Eghbalpoor","year":"2019","journal-title":"Acta Microbiol Immunol Hung"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e00058","DOI":"10.1128\/CMR.00058-18","article-title":"The Enterococcus: a model of adaptability to its environment","volume":"32","author":"Garc\u00eda-Solache","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2147\/IDR.S206084","article-title":"Global prevalence of antibiotic resistance in blood-isolated Enterococcus faecalis and Enterococcus faecium: a systematic review and meta-analysis","author":"Jabbari Shiadeh","year":"2019","journal-title":"Infect Drug Resist"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e1403","DOI":"10.7759\/cureus.1403","article-title":"A review on antibiotic resistance: alarm bells are ringing","volume":"9","author":"Zaman","year":"2017","journal-title":"Cureus"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3934\/microbiol.2018.3.482","article-title":"An overview of the antimicrobial resistance mechanisms of bacteria","volume":"4","author":"Reygaert","year":"2018","journal-title":"AIMS Microbiol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3389\/fmicb.2018.00828","article-title":"The genomic basis of intrinsic and acquired antibiotic resistance in the genus Serratia","volume":"9","author":"Sandner-Miranda","year":"2018","journal-title":"Front Microbiol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.envres.2018.11.040","article-title":"Human health risk assessment of antibiotic resistance associated with antibiotic residues in the environment: a review","volume":"169","author":"Ben","year":"2019","journal-title":"Environ Res"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"a019752","DOI":"10.1101\/cshperspect.a019752","article-title":"Mechanisms of antifungal drug resistance","volume":"5","author":"Cowen","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"S431","DOI":"10.1093\/infdis\/jix179","article-title":"Antifungal resistance: an emerging reality and a global challenge","volume":"216","author":"Kontoyiannis","year":"2017","journal-title":"J Infect Dis"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases\u2013estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"fow043","DOI":"10.1093\/femsyr\/fow043","article-title":"MFS transporters of Candida species and their role in clinical drug resistance","volume":"16","author":"Redhu","year":"2016","journal-title":"FEMS Yeast Res"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"ii13","DOI":"10.1093\/jac\/dkw392","article-title":"The current treatment landscape: candidiasis","volume":"71","author":"Bassetti","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/genes9090461","article-title":"Evolutionary emergence of drug resistance in Candida opportunistic pathogens","volume":"9","author":"Ksiezopolska","year":"2018","journal-title":"Genes"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3314\/jjmm.48.1","article-title":"Trends in the epidemiology of invasive fungal infections","volume":"48","author":"Warnock","year":"2007","journal-title":"Nippon Ishinkin Gakkai Zasshi"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.idc.2015.10.013","article-title":"Invasive candidiasis","volume":"30","author":"McCarty","year":"2016","journal-title":"Infect Dis Clin"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.diii.2015.01.005","article-title":"Pulmonary aspergillosis","volume":"96","author":"Chabi","year":"2015","journal-title":"Diagn Interv Imaging"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e00140","DOI":"10.1128\/CMR.00140-18","article-title":"Aspergillus fumigatus and aspergillosis in 2019","volume":"33","author":"Latg\u00e9","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.idc.2015.10.006","article-title":"Cryptococcosis","volume":"30","author":"Maziarz","year":"2016","journal-title":"Infect Dis Clin"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e00357","DOI":"10.1128\/mSphere.00357-16","article-title":"The case for adopting the \u201cspecies complex\u201d nomenclature for the etiologic agents of cryptococcosis","volume":"2","author":"Kwon-Chung","year":"2017","journal-title":"MSphere"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1016\/j.bmc.2012.04.045","article-title":"The biology and chemistry of antifungal agents: a review","volume":"20","author":"Kathiravan","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"261","DOI":"10.21037\/atm.2016.04.01","article-title":"Harnessing the immune system to improve cancer therapy","volume":"4","author":"Papaioannou","year":"2016","journal-title":"Ann Transl Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3109\/08820139.2015.1093913","article-title":"Immunotherapy of fungal infections","volume":"44","author":"Datta","year":"2015","journal-title":"Immunol Investig"},{"key":"ref62","volume-title":"The Therapeutic Monoclonal Antibody Market MAbs","author":"Ecker","year":"2015"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.chom.2012.04.004","article-title":"Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases","volume":"11","author":"Casadevall","year":"2012","journal-title":"Cell Host Microbe"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nrmicro974","article-title":"Passive antibody therapy for infectious diseases","volume":"2","author":"Casadevall","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"ref65","volume-title":"Encyclopedia of Cancer","author":"Schwab","year":"2008"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.3389\/fmicb.2018.03158","article-title":"Principles of immunotherapy: implications for treatment strategies in cancer and infectious diseases","volume":"9","author":"Naran","year":"2018","journal-title":"Front Microbiol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"E3463","DOI":"10.1073\/pnas.1717295115","article-title":"Global increase and geographic convergence in antibiotic consumption between 2000 and 2015","volume":"115","author":"Klein","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"ref68","author":"O\u2019Neill","year":"2014"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.cmi.2015.12.002","article-title":"The negative impact of antibiotic resistance","volume":"22","author":"Friedman","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.bcp.2016.09.025","article-title":"Antibiotics in late clinical development","volume":"133","author":"Fernandes","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"6427","DOI":"10.1007\/s00253-022-12175-8","article-title":"Antimicrobial resistance: new insights and therapeutic implications","volume":"106","author":"Sheikh","year":"2022","journal-title":"Applied Microbiology and Biotechnology."},{"key":"ref72","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-323-90053-9.00006-3","article-title":"Role of immunogenetics polymorphisms in infectious diseases","volume-title":"A Molecular Approach to Immunogenetics","author":"Qadri","year":"2022"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrmicro.2017.42","article-title":"Persistent bacterial infections and persister cells","volume":"15","author":"Fisher","year":"2017","journal-title":"Nat Rev Microbiol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.tim.2021.05.005","article-title":"Towards efficient immunotherapy for bacterial infection","volume":"30","author":"McCulloch","year":"2022","journal-title":"Trends Microbiol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/QCO.0000000000000539","article-title":"Monoclonal antibody-based therapies for bacterial infections","volume":"32","author":"Motley","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","article-title":"A functional role for antibodies in tuberculosis","volume":"167","author":"Lu","year":"2016","journal-title":"Cells"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cmi.2018.08.004","article-title":"Phase 1 study of MEDI3902, an investigational anti\u2013Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults","volume":"25","author":"Ali","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1093\/infdis\/jiy438","article-title":"Pseudomonas aeruginosa PcrV and Psl, the molecular targets of bispecific antibody MEDI3902, are conserved among diverse global clinical isolates","volume":"218","author":"Tabor","year":"2018","journal-title":"J Infect Dis"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s00134-018-5229-2","article-title":"Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial","volume":"44","author":"Fran\u00e7ois","year":"2018","journal-title":"Intensive Care Med"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"e1009","DOI":"10.1002\/cti2.1009","article-title":"Characterisation of anti-alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against Staphylococcus aureus alpha toxin","volume":"7","author":"Ruzin","year":"2018","journal-title":"Clin Transl Immunol"},{"key":"ref81","year":"2020"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"e00100","DOI":"10.1007\/s10096-020-03843-6","article-title":"Tuberculosis vaccine development: progress in clinical evaluation","volume":"33","author":"Sable","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S2213-2600(15)00037-5","article-title":"Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial","volume":"3","author":"Ndiaye","year":"2015","journal-title":"Lancet Respir Med"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl J Med"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3389\/fimmu.2020.01755","article-title":"Challenges for clinical development of vaccines for prevention of hospital-acquired bacterial infections","volume":"11","author":"Bekeredjian-Ding","year":"2020","journal-title":"Front Immunol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"632","DOI":"10.4161\/hv.34414","article-title":"Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study","volume":"11","author":"Fattom","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1001\/jama.2013.3010","article-title":"Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial","volume":"309","author":"Fowler","year":"2013","journal-title":"JAMA"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1586\/14760584.2014.890053","article-title":"Vaccines for Pseudomonas aeruginosa: a long and winding road","volume":"13","author":"Priebe","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"11020","DOI":"10.1073\/pnas.0702403104","article-title":"A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients","volume":"104","author":"D\u00f6ring","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1128\/iai.62.9.3972-3979.1994","article-title":"Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine","volume":"62","author":"Pier","year":"1994","journal-title":"Infect Immun"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-017-1601-9","article-title":"A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients","volume":"21","author":"Rello","year":"2017","journal-title":"Crit Care"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.3389\/fimmu.2018.03021","article-title":"Genome-based approach delivers vaccine candidates against Pseudomonas aeruginosa","volume":"9","author":"Bianconi","year":"2019","journal-title":"Front Immunol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"18655","DOI":"10.1073\/pnas.1907833116","article-title":"A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae","volume":"116","author":"Feldman","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1038\/emm.2015.59","article-title":"Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity","volume":"47","author":"Lee","year":"2015","journal-title":"Exp Mol Med"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41579-020-00506-3","article-title":"The role of vaccines in combatting antimicrobial resistance","volume":"19","author":"Micoli","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Immune checkpoint blockade in infectious diseases","volume":"18","author":"Wykes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.3389\/fimmu.2018.01995","article-title":"PD-1 expression on Mycobacterium tuberculosis-specific CD4 T cells is associated with bacterial load in human tuberculosis","volume":"9","author":"Day","year":"2018","journal-title":"Front Immunol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"eaat2702","DOI":"10.1126\/scitranslmed.aat2702","article-title":"Tuberculosis following PD-1 blockade for cancer immunotherapy","volume":"11","author":"Barber","year":"2019","journal-title":"Sci Transl Med"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"13402","DOI":"10.1073\/pnas.1007394107","article-title":"Programmed death-1 (PD-1)\u2013deficient mice are extraordinarily sensitive to tuberculosis","volume":"107","author":"L\u00e1z\u00e1r-Moln\u00e1r","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"e52668","DOI":"10.7554\/eLife.52668","article-title":"Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-\u03b1","volume":"9","author":"Tezera","year":"2020","journal-title":"elife"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"e000866","DOI":"10.1136\/esmoopen-2020-000866","article-title":"Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors","volume":"5","author":"Anand","year":"2020","journal-title":"ESMO Open"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"e1005490","DOI":"10.1371\/journal.ppat.1005490","article-title":"TIM3 mediates T cell exhaustion during Mycobacterium tuberculosis infection","volume":"12","author":"Jayaraman","year":"2016","journal-title":"PLoS Pathog"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"e0180413","DOI":"10.1371\/journal.pone.0180413","article-title":"LAG-3 potentiates the survival of Mycobacterium tuberculosis in host phagocytes by modulating mitochondrial signaling in an in-vitro granuloma model","volume":"12","author":"Phillips","year":"2017","journal-title":"PLoS One"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","article-title":"Immune checkpoint inhibitors and tuberculosis: an old disease in a new context","volume":"21","author":"Langan","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3389\/fimmu.2020.02107","article-title":"Harnessing unconventional T cells for immunotherapy of tuberculosis","volume":"11","author":"La Manna","year":"2020","journal-title":"Front Immunol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"ltaa007","DOI":"10.1093\/immadv\/ltaa007","article-title":"Recent advances in immunotherapies against infectious diseases","volume":"1","author":"Ramamurthy","year":"2021","journal-title":"Immunother Adv"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cytogfr.2016.07.003","article-title":"Opposing roles of IL-10 in acute bacterial infection","volume":"32","author":"Pe\u00f1aloza","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.tim.2021.05.005","article-title":"Towards efficient immunotherapy for bacterial infection","volume":"30","author":"McCulloch","year":"2022","journal-title":"Trends Microbiol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Drug Discov"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1038\/s41423-020-0439-2","article-title":"Albumin fusion with granulocyte-macrophage colony-stimulating factor acts as an immunotherapy against chronic tuberculosis","volume":"18","author":"Chuang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"e98960","DOI":"10.1172\/jci.insight.98960","article-title":"Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial","volume":"3","author":"Francois","year":"2018","journal-title":"JCI Insight"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"e1007405","DOI":"10.1371\/journal.ppat.1007405","article-title":"Polymicrobial sepsis influences NK-cell-mediated immunity by diminishing NK-cell-intrinsic receptor-mediated effector responses to viral ligands or infections","volume":"14","author":"Jensen","year":"2018","journal-title":"PLoS Pathog"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ebiom.2016.02.025","article-title":"Low circulating natural killer cell counts are associated with severe disease in patients with common variable immunodeficiency","volume":"6","author":"Ebbo","year":"2016","journal-title":"EBioMedicine"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/ijcp.12382","article-title":"Anti-TNF-\u03b1 therapy for patients with sepsis: a systematic meta-analysis","volume":"68","author":"Lv","year":"2014","journal-title":"Int J Clin Pract"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1097\/CCM.0b013e3182982add","article-title":"Anti-tumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis","volume":"41","author":"Qiu","year":"2013","journal-title":"Crit Care Med"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/oxfordjournals.jbchem.a022636","article-title":"Expression of cytokines in bacterial and viral infections and their biochemical aspects","volume":"127","author":"Imanishi","year":"2000","journal-title":"J Biochem"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"e02588","DOI":"10.1128\/AAC.02588-18","article-title":"A phase 1, randomized, single-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S, an anti-Staphylococcus aureus thiomab antibody-antibiotic conjugate, in healthy volunteers","volume":"63","author":"Peck","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibioticresistancein Pseudomonas aeruginosa: mechanismsand alternativetheraG peuticstrategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol Adv"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1126\/science.aap7999","article-title":"Worldwide emergence of resistance to antifungal drugs challenges human health and food security","volume":"360","author":"Fisher","year":"2018","journal-title":"Science"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/jof5030067","article-title":"Emerging fungal infections: new patients, new patterns, and new pathogens","volume":"5","author":"Friedman","year":"2019","journal-title":"J Fungi"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-07738-1","article-title":"Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis","volume":"9","author":"Rudkin","year":"2018","journal-title":"Nat Commun"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"103713","DOI":"10.1016\/j.fgb.2022.103713","article-title":"Quinidine drug resistance transporter knockout Candida cells modulate glucose transporter expression and accumulate metabolites leading to enhanced azole drug resistance","volume":"161","author":"Qadri","year":"2022","journal-title":"Fungal Genetics and Biology"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"e0215535","DOI":"10.1371\/journal.pone.0215535","article-title":"Novel mouse monoclonal antibodies specifically recognizing \u03b2-(1\u2192 3)-D-glucan antigen","volume":"14","author":"Matveev","year":"2019","journal-title":"PLoS One"},{"key":"ref129","doi-asserted-by":"crossref","DOI":"10.52305\/RDUL1056","volume-title":"Cytokines and their therapeutic potential","author":"Mir","year":"2020"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/HAB-190390","article-title":"Nanobodies: The \u201cMagic Bullets\u201d in therapeutics, drug delivery and diagnostics","volume":"28","author":"Mir","year":"2020","journal-title":"Hum. Antibodies"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"480","DOI":"10.2174\/1389201021666200628021702","article-title":"Development of new therapeutics to meet the current challenge of drug resistant tuberculosis","volume":"22","author":"Sheikh","year":"2021","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref132","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/B978-0-12-802585-7.00006-6","article-title":"T-Cell costimulation and its applications in diseases,","volume-title":"Developing Costimulatory Molecules for Immunotherapy of Diseases","author":"Mir","year":"2015"},{"key":"ref133","first-page":"141","article-title":"Costimulation and costimulatory molecules in cancer and tuberculosis","volume-title":"Cancer and Infectious Diseases","author":"Mir","year":"2013"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/14712598.2017.1322576","article-title":"Promising immunotherapy against fungal diseases","volume":"17","author":"Posch","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S1471-4906(03)00228-X","article-title":"Antibody-mediated regulation of cellular immunity and the inflammatory response","volume":"24","author":"Casadevall","year":"2003","journal-title":"Trends Immunol"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.micinf.2007.08.001","article-title":"A surface 75-kDa protein with acid phosphatase activity recognized by monoclonal antibodies that inhibit Paracoccidioides brasiliensis growth","volume":"9","author":"Xander","year":"2007","journal-title":"Microbes Infect"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"e00085","DOI":"10.1128\/mSphere.00085-15","article-title":"Antibody binding alters the characteristics and contents of extracellular vesicles released by Histoplasma capsulatum","volume":"1","author":"Matos Baltazar","year":"2016","journal-title":"MSphere"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-25665-5","article-title":"Concentration-dependent protein loading of extracellular vesicles released by Histoplasma capsulatum after antibody treatment and its modulatory action upon macrophages","volume":"8","author":"Baltazar","year":"2018","journal-title":"Sci Rep"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"G38","DOI":"10.1016\/j.vaccine.2009.09.105","article-title":"Monoclonal antibody-based therapies for microbial diseases","volume":"27","author":"Saylor","year":"2009","journal-title":"Vaccine"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/jof6010031","article-title":"Immunotherapy against systemic fungal infections based on monoclonal antibodies","volume":"6","author":"Boniche","year":"2020","journal-title":"J Fungi"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1128\/iai.63.11.4211-4218.1995","article-title":"Antibody immunity and invasive fungal infections","volume":"63","author":"Casadevall","year":"1995","journal-title":"Infect Immun"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1128\/iai.43.2.574-579.1984","article-title":"Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils","volume":"43","author":"Kozel","year":"1984","journal-title":"Infect Immun"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1128\/iai.51.2.556-562.1986","article-title":"Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans","volume":"51","author":"Nabavi","year":"1986","journal-title":"Infect Immun"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"176","DOI":"10.7326\/0003-4819-80-2-176","article-title":"Prognostic factors in cryptococcal meningitis: a study in 111 cases","volume":"80","author":"Rd","year":"1974","journal-title":"Ann Intern Med"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"45","DOI":"10.7326\/0003-4819-69-1-45","article-title":"Serology of human cryptococcosis","volume":"69","author":"Bindschadler","year":"1968","journal-title":"Ann Intern Med"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1128\/iai.64.8.2897-2903.1996","article-title":"Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils","volume":"64","author":"Retini","year":"1996","journal-title":"Infect Immun"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/mmy.38.6.407.417","article-title":"Immunoregulation by capsular components of Cryptococcus neoformans","volume":"38","author":"Vecchiarelli","year":"2000","journal-title":"Med Mycol"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1128\/iai.63.9.3448-3453.1995","article-title":"Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody","volume":"63","author":"Goldman","year":"1995","journal-title":"Infect Immun"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1128\/iai.62.3.1079-1088.1994","article-title":"Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice","volume":"62","author":"Mukherjee","year":"1994","journal-title":"Infect Immun"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1128\/iai.63.2.573-579.1995","article-title":"Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages","volume":"63","author":"Mukherjee","year":"1995","journal-title":"Infect Immun"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0165-5728(95)00097-L","article-title":"Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody","volume":"62","author":"Lee","year":"1995","journal-title":"J Neuroimmunol"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/infdis\/163.5.1114","article-title":"Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action","volume":"163","author":"Dromer","year":"1991","journal-title":"J Infect Dis"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1128\/AAC.49.3.952-958.2005","article-title":"Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis","volume":"49","author":"Larsen","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.diagmicrobio.2004.08.013","article-title":"Evaluation of Mycograb\u00ae, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies","volume":"51","author":"Nooney","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1128\/jb.150.3.1414-1421.1982","article-title":"Melanin-lacking mutants of Cryptococcus neoformans and their virulence for mice","volume":"150","author":"Kwon-Chung","year":"1982","journal-title":"J Bacteriol"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(00)02356-4","article-title":"Melanisation of Cryptococcus neoformans in human brain tissue","volume":"355","author":"Nosanchuk","year":"2000","journal-title":"Lancet"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1128\/IAI.69.5.3410-3412.2001","article-title":"Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection","volume":"69","author":"Rosas","year":"2001","journal-title":"Infect Immun"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"790","DOI":"10.4049\/jimmunol.158.2.790","article-title":"Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection","volume":"158","author":"Feldmesser","year":"1997","journal-title":"J Immunol"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1084\/jem.185.4.685","article-title":"Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy","volume":"185","author":"Nussbaum","year":"1997","journal-title":"J Exp Med"},{"key":"ref160","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.4049\/jimmunol.166.3.2100","article-title":"Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments","volume":"166","author":"Taborda","year":"2001","journal-title":"J Immunol"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1128\/IAI.70.5.2598-2604.2002","article-title":"Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3","volume":"70","author":"Shapiro","year":"2002","journal-title":"Infect Immun"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1073\/pnas.94.6.2483","article-title":"T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice","volume":"94","author":"Yuan","year":"1997","journal-title":"Proc Natl Acad Sci"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566524054022567","article-title":"Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans","volume":"5","author":"Casadevall","year":"2005","journal-title":"Curr Mol Med"},{"key":"ref164","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.1016\/j.vaccine.2017.08.082","article-title":"The vaccines and antibodies associated with Als3p for treatment of Candida albicans infections","volume":"35","author":"Sui","year":"2017","journal-title":"Vaccine"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1128\/AAC.00892-10","article-title":"Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans","volume":"55","author":"Brena","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref166","first-page":"3639","article-title":"Cross-reactivity between Candida albicans and oral squamous cell carcinoma revealed by monoclonal antibody C7","volume":"27","author":"Rodriguez","year":"2007","journal-title":"Anticancer Res"},{"key":"ref167","doi-asserted-by":"publisher","first-page":"14912","DOI":"10.1074\/jbc.M111.322362","article-title":"\u03b2-Actin-binding complementarity-determining region 2 of variable heavy chain from monoclonal antibody C7 induces apoptosis in several human tumor cells and is protective against metastatic melanoma","volume":"287","author":"Arruda","year":"2012","journal-title":"J Biol Chem"},{"key":"ref168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/403121","article-title":"Human monoclonal antibody-based therapy in the treatment of invasive candidiasis","volume":"2013","author":"Bugli","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"ref169","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1128\/AAC.47.7.2208-2216.2003","article-title":"Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90","volume":"47","author":"Matthews","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref170","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s12272-011-0307-9","article-title":"Combination immunotherapy of MAb B6. 1 with fluconazole augments therapeutic effect to disseminated candidiasis","volume":"34","author":"Lee","year":"2011","journal-title":"Arch Pharm Res"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.intimp.2010.08.027","article-title":"Efficacy of combination immunotherapy of IgM MAb B6. 1 and amphotericin B against disseminated candidiasis","volume":"10","author":"Han","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.vetimm.2008.04.020","article-title":"Immune response to fungal infections","volume":"125","author":"Blanco","year":"2008","journal-title":"Vet Immunol Immunopathol"},{"key":"ref173","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.micpath.2015.01.003","article-title":"A monoclonal antibody against glycoproteins of Aspergillus fumigatus shows anti-adhesive potential","volume":"79","author":"Kumar","year":"2015","journal-title":"Microb Pathog"},{"key":"ref174","doi-asserted-by":"publisher","first-page":"fnz015","DOI":"10.1093\/femsle\/fnz015","article-title":"A novel monoclonal antibody against enolase antigen of aspergillus fumigatus protects experimental aspergillosis in mice","volume":"366","author":"Yadav","year":"2019","journal-title":"FEMS Microbiol Lett"},{"key":"ref175","doi-asserted-by":"publisher","first-page":"e5780","DOI":"10.1371\/journal.pone.0005780","article-title":"Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion","volume":"4","author":"Stie","year":"2009","journal-title":"PLoS One"},{"key":"ref176","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"ref177","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1128\/iai.60.3.735-741.1992","article-title":"Inhibition of Aspergillus fumigatus elastase with monoclonal antibodies produced by using denatured elastase as an immunogen","volume":"60","author":"Frosco","year":"1992","journal-title":"Infect Immun"},{"key":"ref178","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1128\/CDLI.12.9.1063-1068.2005","article-title":"Monoclonal immunoglobulin G1 directed against Aspergillus fumigatus cell wall glycoprotein protects against experimental murine aspergillosis","volume":"12","author":"Chaturvedi","year":"2005","journal-title":"Clin Vaccine Immunol"},{"key":"ref179","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.4049\/jimmunol.1401940","article-title":"Antibodies generated against streptococci protect in a mouse model of disseminated aspergillosis","volume":"194","author":"Wharton","year":"2015","journal-title":"J Immunol"},{"key":"ref180","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2012.02.012","article-title":"Beyond empiricism: informing vaccine development through innate immunity research","volume":"148","author":"Levitz","year":"2012","journal-title":"Cells"},{"key":"ref181","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1248\/bpb.b19-00841","article-title":"Vaccines and protective immune memory against cryptococcosis","volume":"43","author":"Ueno","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"ref182","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-96127-1.00003-6","volume-title":"Recent trends in the development of bacterial and fungal vaccines","author":"Mir","year":"2022"},{"key":"ref183","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.tim.2017.10.002","article-title":"A call to arms: quest for a cryptococcal vaccine","volume":"26","author":"Van Dyke","year":"2018","journal-title":"Trends Microbiol"},{"key":"ref184","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/mmy\/myw081","article-title":"Aspergillus vaccines: hardly worth studying or worthy of hard study?","volume":"55","author":"Levitz","year":"2016","journal-title":"Sabouraudia"},{"key":"ref185","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.biopha.2018.10.075","article-title":"Fungal vaccines, mechanism of actions and immunology: a comprehensive review","volume":"109","author":"Nami","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"ref186","doi-asserted-by":"publisher","first-page":"11109","DOI":"10.1021\/acs.chemrev.5b00109","article-title":"Synthetic nanoparticles for vaccines and immunotherapy","volume":"115","author":"Irvine","year":"2015","journal-title":"Chem Rev"},{"key":"ref187","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/499811","article-title":"Immunotherapy for fungal infections","volume":"42","author":"Segal","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref188","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1016\/j.vaccine.2013.09.016","article-title":"NDV-3 protects mice from vulvovaginal candidiasis through T-and B-cell immune response","volume":"31","author":"Ibrahim","year":"2013","journal-title":"Vaccine"},{"key":"ref189","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-57906-x","article-title":"In silico design of a multivalent vaccine against Candida albicans","volume":"10","author":"Tarang","year":"2020","journal-title":"Sci Rep"},{"key":"ref190","doi-asserted-by":"publisher","first-page":"e00547","DOI":"10.1128\/mBio.00547-16","article-title":"Induction of protective immunity to cryptococcal infection in mice by a heat-killed, chitosan-deficient strain of Cryptococcus neoformans","volume":"7","author":"Upadhya","year":"2016","journal-title":"MBio"},{"key":"ref191","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","article-title":"Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation","volume":"106","author":"Perruccio","year":"2005","journal-title":"Blood"},{"key":"ref192","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-021-00294-8","article-title":"Vaccines for human fungal diseases: close but still a long way to go","volume":"6","author":"Oliveira","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref193","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/INF.0000000000001028","article-title":"Successful granulocyte colony-stimulating factor treatment of relapsing Candida albicans meningoencephalitis caused by CARD9 deficiency","volume":"35","author":"Celmeli","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"ref194","doi-asserted-by":"publisher","first-page":"101417","DOI":"10.1016\/j.cimid.2020.101417","article-title":"Complete clinical remission of invasive Candida infection with CARD9 deficiency after G-CSF treatment","volume":"70","author":"Du","year":"2020","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"ref195","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/cid\/ciu215","article-title":"CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission with GM-CSF therapy","volume":"59","author":"Gavino","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref196","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10875-016-0364-4","article-title":"Disseminated cryptococcosis due to anti-granulocyte-macrophage colony-stimulating factor autoantibodies in the absence of pulmonary alveolar proteinosis","volume":"37","author":"Kuo","year":"2017","journal-title":"J Clin Immunol"},{"key":"ref197","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s15010-008-7378-7","article-title":"Interferon-\u03b3 and granulocyte-macrophage colony stimulating factor therapy in three patients with pulmonary aspergillosis","volume":"36","author":"Bandera","year":"2008","journal-title":"Infection"},{"key":"ref198","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/cncr.21142","article-title":"Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia","volume":"104","author":"Dignani","year":"2005","journal-title":"Cancer"},{"key":"ref199","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/j.1600-6143.2010.03094.x","article-title":"Exogenous interferon-\u03b3 immunotherapy for invasive fungal infections in kidney transplant patients","volume":"10","author":"Armstrong-James","year":"2010","journal-title":"Am J Transplant"},{"key":"ref200","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1089\/088922201750251981","article-title":"A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease","volume":"17","author":"Riddell","year":"2001","journal-title":"AIDS Res Hum Retrovir"},{"key":"ref201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-14-166","article-title":"Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series","volume":"14","author":"Delsing","year":"2014","journal-title":"BMC Infect Dis"},{"key":"ref202","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jcyt.2017.08.012","article-title":"Granulocyte transfusions: a concise review for practitioners","volume":"19","author":"Gea-Banacloche","year":"2017","journal-title":"Cytotherapy"},{"key":"ref203","doi-asserted-by":"publisher","first-page":"e0159569","DOI":"10.1371\/journal.pone.0159569","article-title":"Dose-dependent effect of granulocyte transfusions in hematological patients with febrile neutropenia","volume":"11","author":"Teofili","year":"2016","journal-title":"PLoS One"},{"key":"ref204","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1182\/blood-2003-03-0748","article-title":"A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation","volume":"102","author":"Bozza","year":"2003","journal-title":"Blood"},{"key":"ref205","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.3390\/ijms20133166","article-title":"Phase I clinical trial using autologous ex vivo expanded NK cells and cytotoxic T lymphocytes for cancer treatment in Vietnam","volume":"20","author":"Liem","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref206","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/bmt.2012.162","article-title":"Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers","volume":"48","author":"Stern","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"ref207","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fimmu.2013.00276","article-title":"Monitoring of pathogen-specific T-cell immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"4","author":"Fuji","year":"2013","journal-title":"Front Immunol"},{"key":"ref208","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/s41409-019-0501-9","article-title":"Clinical-scale production of Aspergillus-specific T cells for the treatment of invasive aspergillosis in the immunocompromised host","volume":"54","author":"Papadopoulou","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"ref209","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.mib.2020.09.007","article-title":"Immunotherapeutic approaches for fungal infections","volume":"58","author":"Williams","year":"2020","journal-title":"Curr Opin Microbiol"},{"key":"ref210","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"ref211","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"ref212","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"ref213","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"ref214","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1073\/pnas.1312789111","article-title":"Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection","volume":"111","author":"Kumaresan","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"ref215","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.3389\/fimmu.2017.01939","article-title":"Methods of controlling invasive fungal infections using CD8+ T cells","volume":"8","author":"Kumaresan","year":"2018","journal-title":"Front Immunol"},{"key":"ref216","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMcibr1917242","article-title":"Activating immunity to fight a foe\u2013a new path","volume":"382","author":"Hotchkiss","year":"2020","journal-title":"N Engl J Med"},{"key":"ref217","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0950-3536(11)80022-3","article-title":"Anaemia of plasmodium falciparum malaria","volume":"5","author":"Phillips","year":"1992","journal-title":"Baillieres Clin Haematol"},{"key":"ref218","doi-asserted-by":"publisher","first-page":"e0007860","DOI":"10.1371\/journal.pntd.0007860","article-title":"Reassessing therapeutic antibodies for neglected and tropical diseases","volume":"14","author":"Hooft van Huijsduijnen","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"ref219","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/17476348.2018.1457439","article-title":"The use of immunotherapy for the treatment of tuberculosis","volume":"12","author":"Ramos-Espinosa","year":"2018","journal-title":"Expert Rev Respir Med"},{"key":"ref220","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3389\/fimmu.2017.00688","article-title":"Applying precision medicine and immunotherapy advances from oncology to host-directed therapies for infectious diseases","volume":"8","author":"Mahon","year":"2017","journal-title":"Front Immunol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-802585-7.00001-7","article-title":"Chapter 1-Introduction to costimulation and costimulatory molecules","volume-title":"Developing Costimulatory Molecules for Immunotherapy of Diseases","author":"Mir","year":"2015"},{"key":"ref222","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2217\/fmb-2022-0026","article-title":"Manipulation and exploitation of host immune system by pathogenic Mycobacterium tuberculosis for its advantage","volume":"17","author":"Mir","year":"2022","journal-title":"Future Microbiol."},{"key":"ref223","doi-asserted-by":"publisher","DOI":"10.5530\/ijpi.2022.2.30","article-title":"A novel prognostic biomarker with potential of high diagnostic accuracy in pulmonary tuberculosis: An in silico study","volume":"12","author":"Sheikh","year":"2022","journal-title":"Int. J. Pharm. Investig."},{"key":"ref224","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3390\/microorganisms8081201","article-title":"Leishmania immunity: advancing immunotherapy and vaccine development","volume":"8","author":"Ikeogu","year":"2020","journal-title":"Microorganisms"},{"key":"ref225","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/vaccines7040122","article-title":"Enlisting the mRNA vaccine platform to combat parasitic infections","volume":"7","author":"Versteeg","year":"2019","journal-title":"Vaccine"},{"key":"ref226","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"key":"ref227","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41579-020-00441-3","article-title":"Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa","volume":"18","author":"Margolin","year":"2020","journal-title":"Nat Rev Microbiol"}],"updated-by":[{"DOI":"10.3389\/fmed.2024.1518352","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000}},{"DOI":"10.3389\/fmed.2024.1518352","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"record-id":"68035"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1135541\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T19:42:44Z","timestamp":1702237364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1135541\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":227,"alternative-id":["10.3389\/fmed.2023.1135541"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1135541","relation":{"retraction":[{"id-type":"doi","id":"10.3389\/fmed.2024.1518352","asserted-by":"object"}]},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"article-number":"1135541"}}